The absence of myocardial calcium-independent phospholipase a2γ results in impaired prostaglandin e2 production and decreased survival in mice with acute trypanosoma cruzi infection by Sharma, Janhavi et al.




The absence of myocardial calcium-independent
phospholipase a2γ results in impaired
prostaglandin e2 production and decreased survival










Washington University School of Medicine in St. Louis
See next page for additional authors
Follow this and additional works at: http://digitalcommons.wustl.edu/open_access_pubs
This Open Access Publication is brought to you for free and open access by Digital Commons@Becker. It has been accepted for inclusion in Open
Access Publications by an authorized administrator of Digital Commons@Becker. For more information, please contact engeszer@wustl.edu.
Recommended Citation
Sharma, Janhavi; Eickhoff, Christopher S.; Hoft, Daniel F.; Ford, David A.; Gross, Richard W.; and McHowat, Jane, ,"The absence of
myocardial calcium-independent phospholipase a2γ results in impaired prostaglandin e2 production and decreased survival in mice
with acute trypanosoma cruzi infection." Infection and Immunity.81,7. 2278-2287. (2013).
http://digitalcommons.wustl.edu/open_access_pubs/2552
Authors
Janhavi Sharma, Christopher S. Eickhoff, Daniel F. Hoft, David A. Ford, Richard W. Gross, and Jane McHowat
This open access publication is available at Digital Commons@Becker: http://digitalcommons.wustl.edu/open_access_pubs/2552
  Published Ahead of Print 19 February 2013. 
2013, 81(7):2278. DOI: 10.1128/IAI.00497-12. Infect. Immun. 
David A. Ford, Richard W. Gross and Jane McHowat
Janhavi Sharma, Christopher S. Eickhoff, Daniel F. Hoft,
 
with Acute Trypanosoma cruzi Infection
Production and Decreased Survival in Mice 2
Results in Impaired Prostaglandin E
γ2Calcium-Independent Phospholipase A
The Absence of Myocardial
http://iai.asm.org/content/81/7/2278




This article cites 38 articles, 13 of which can be accessed free
CONTENT ALERTS
 more»articles cite this article), 
Receive: RSS Feeds, eTOCs, free email alerts (when new
http://journals.asm.org/site/misc/reprints.xhtmlInformation about commercial reprint orders: 




arch 31, 2014 by W










arch 31, 2014 by W







The Absence of Myocardial Calcium-Independent Phospholipase A2
Results in Impaired Prostaglandin E2 Production and Decreased
Survival in Mice with Acute Trypanosoma cruzi Infection
Janhavi Sharma,a Christopher S. Eickhoff,b Daniel F. Hoft,b David A. Ford,c Richard W. Gross,d Jane McHowata
Department of Pathology,a Division of Infectious Diseases, Department of Internal Medicine,b and Department of Biochemistry and Molecular Biology and Center for
Cardiovascular Research,c Saint Louis University School of Medicine, St. Louis, Missouri, USA; Division of Bioorganic Chemistry and Molecular Pharmacology, Department
of Medicine, and Department of Chemistry, Washington University School of Medicine in St. Louis, St. Louis, Missouri, USAd
Cardiomyopathy is a serious complication of Chagas’ disease, caused by the protozoan parasite Trypanosoma cruzi. The parasite
often infects cardiac myocytes, causing the release of inflammatory mediators, including eicosanoids. A recent study from our
laboratory demonstrated that calcium-independent phospholipase A2 (iPLA2) accounts for the majority of PLA2 activity in
rabbit ventricular myocytes and is responsible for arachidonic acid (AA) and prostaglandin E2 (PGE2) release. Thus, we hypothe-
sized that cardiac iPLA2 contributes to eicosanoid production in T. cruzi infection. Inhibition of the isoform iPLA2 or
iPLA2, with the R or S enantiomer of bromoenol lactone (BEL), respectively, demonstrated that iPLA2 is the predominant
isoform in immortalized mouse cardiac myocytes (HL-1 cells). Stimulation of HL-1 cells with thrombin, a serine protease associ-
ated with microthrombus formation in Chagas’ disease and a known activator of iPLA2, increased AA and PGE2 release, accom-
panied by platelet-activating factor (PAF) production. Similarly, T. cruzi infection resulted in increased AA and PGE2 release
over time that was inhibited by pretreatment with (R)-BEL. Further, T. cruzi-infected iPLA2-knockout (KO) mice had lower
survival rates and increased tissue parasitism compared to wild-type (WT) mice, suggesting that iPLA2-KO mice were more
susceptible to infection than WT mice. A significant increase in iPLA2 activity was observed in WT mice following infection,
whereas iPLA2-KO mice showed no alteration in cardiac iPLA2 activity and produced less PGE2. In summary, these studies
demonstrate that T. cruzi infection activates cardiac myocyte iPLA2, resulting in increased AA and PGE2 release, mediators that
may be essential for host survival during acute infection. Thus, these studies suggest that iPLA2 plays a cardioprotective role
during the acute stage of Chagas’ disease.
Worldwide, almost 10 million people are infected withTrypanosoma cruzi, the causative agent of Chagas’ disease
(1). Initially confined mostly to South America, global migration,
blood products, organ transplantation, and congenital transmis-
sion have contributed to the spread of the disease, particularly
in areas of nonendemicity. Millions of people are now at risk
for contracting the infection, and in the United States alone, it
is estimated that more than 300,000 people are infected with T.
cruzi (2).
The organ primarily affected by Chagas’ disease is the heart.
The disease progresses from an acute stage, followed by the inde-
terminate stage, to the chronic stages. The acute stage of the dis-
ease may or may not be symptomatic, and if present, symptoms
are usually nonspecific, such as fever, chills, and nausea. Cardiac
involvement at the acute stage is rare but can occur in a small
number of infected people, leading to myocarditis and sudden
death. The indeterminate phase is devoid of any clinical presenta-
tion and may last for several decades. Among infected patients,
approximately 30% develop chronic disease with cardiac involve-
ment (3, 4). Chronic Chagas’ heart disease includes arrhythmias,
thromboembolic events, and congestive heart disease, leading to
sudden death (5). A key pathological feature of Chagas’ disease is
inflammation, which is regulated by several mediators, including
adhesion molecules, cytokines, eicosanoids, and nitric oxide (6–
8). In the acute stage, these molecules are seen to be important for
the development of host resistance, as well as regulating progres-
sion to the chronic stages of the disease (9). However, much re-
mains unknown about the host-parasite interactions that contrib-
ute to Chagas’ disease via these mediators. A better understanding
of the complex relationship between the parasite, its target organ,
and the cascade of events following infection will give us valuable
information regarding a major human disease that we still have
very limited means to treat.
Following infection, the parasites move across the endothe-
lium and vascular tissue to gain access to the myocardium. After
penetrating cardiac myocytes, the parasites divide intracellularly
before causing the cell to rupture, releasing more parasites that
can then spread and infect other cells. This cycle of infection and
multiplication of the parasites, resulting in host cell lysis, directly
causes tissue injury in the myocardium. Myocytes also contribute
indirectly to disease progression via cytokine, chemokine, and re-
active oxygen species (ROS) production, accompanied by changes
in myocyte morphology (8, 10, 11).
The release of arachidonic acid from membrane phospholip-
ids, catalyzed by phospholipase A2 (PLA2), is the rate-limiting step
in eicosanoid formation. Arachidonic acid is converted to prosta-
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glandins via the activity of cyclooxygenase enzymes. The accom-
panying lysophospholipid can be converted to platelet-activating
factor (PAF) following a transacetylation reaction. PAF is a potent
molecule involved in the recruitment and activation of inflamma-
tory cells under a variety of pathophysiological circumstances.
Hence, using a single substrate, PLA2 enzymes can contribute to
the generation of a variety of bioactive lipids with a well-estab-
lished role in inflammation.
Several studies have described the presence of platelet aggrega-
tion and thrombus formation with the progress of Chagas’ disease
(5, 12). Thrombin is an important serine protease involved in
thrombus formation that is known to activate calcium-indepen-
dent PLA2 (iPLA2) in ventricular myocytes (13) and thus could
exacerbate the production of bioactive lipid metabolites following
T. cruzi infection. Previous studies from our laboratory have
shown that the majority of the PLA2 activity in rabbit ventricular
myocytes is membrane associated, calcium independent, and me-
diated by the gamma isoform (iPLA2) of the enzyme (14, 15).
Additionally, iPLA2 mediates arachidonic acid and prostaglan-
din E2 (PGE2) release from rabbit ventricular myocytes following
stimulation with tryptase, another important protease that is re-
leased from activated mast cells (16).
The role of iPLA2 in Chagas’ disease remains unexplored, de-
spite the fact that it is an important enzyme that produces several
membrane phospholipid-derived inflammatory mediators in the
myocardium, including eicosanoids and PAF. Since previous
studies have demonstrated an increase in eicosanoids in T. cruzi
infection, it is valuable to know the signal transduction pathways
involved in eicosanoid production. It is not known whether the
parasite activates iPLA2 directly during infection. However, T.
cruzi infection is associated with increased thrombin activation,
and we have demonstrated increased cardiomyocyte iPLA2 activ-
ity in response to thrombin. The aim of this study was to deter-
mine the contribution of iPLA2 in arachidonic acid release and
eicosanoid production in response to T. cruzi infection and to
compare this outcome to the effect of thrombin stimulation. In
vitro studies using immortalized mouse cardiac myocytes (HL-1
cells) were performed in the presence of the pharmacological in-
hibitors (R)- and (S)-bromoenol lactone (BEL) to discriminate
between the two major isoforms, iPLA2 and iPLA2, respec-
tively. To understand the contribution of this enzyme in a more
physiologically relevant setting, in vivo studies were carried out
using T. cruzi-infected iPLA2-knockout (KO) and wild-type
(WT) mice.
MATERIALS AND METHODS
Cell culture. The HL-1 cardiomyocyte cell line, derived from the AT-1
mouse atrial cardiac myocyte cell line, was obtained from W. Claycomb
(Louisiana State University Medical Center, New Orleans, LA, USA) (17).
Cells were grown in flasks/culture dishes coated overnight, at 37°C, with
0.5% fibronectin in 0.02% gelatin. Cells were propagated in Claycomb
medium (SAFC Biosciences, Lenexa, KS) supplemented with 10% fetal
bovine serum (FBS), 2 mM L-glutamine, 0.1 mM norepinephrine, 100
units penicillin, and 100 g streptomycin/ml. Cells were infected with T.
cruzi when they reached confluence and attained a beating phenotype.
Parasites and infection of HL-1 cells. Tissue culture trypomastigotes
(TCT) from the Brazil strain of T. cruzi were propagated in 3T3 mouse
embryonic fibroblasts grown in Dulbecco’s modified Eagle’s medium
(DMEM) supplemented with 2% neonatal calf serum. The 3T3 cells were
infected withT. cruzi on reaching 60% confluence. Infected cells ruptured
following parasite multiplication, releasing a large number of parasites.
The supernatant containing the parasites was collected, and parasite num-
bers were determined using a Neubauer hemocytometer. HL-1 cells,
grown to confluence in the appropriate culture dish, were counted, and a
multiplicity of infection (MOI) of 0.2 was used to infect the cells. Parasites
and HL-1 cells were fed Claycomb medium supplemented with 2% FBS,
and the appropriate number of parasites were then added to each culture
dish. To prepare Tulahuén strain blood form trypomastigotes (BFT),
BALB/c or C.B-17 SCID mice were infected subcutaneously with 5,000 to
20,000 BFT. After 12 to 16 days, the animals were sacrificed and bled by
decapitation into 50-ml conical tubes containing 5 l of heparin (1,000
U/ml)/animal. The concentration of BFT/ml was determined by hemocy-
tometer counts with heparinized blood samples diluted 1:10 with phos-
phate-buffered saline (PBS).
Mice and infections. Animal protocols were in strict accordance with
the National Institutes of Health guidelines for humane treatment of an-
imals and were reviewed and approved by the Animal Care and Use Com-
mittee of Saint Louis University. C57BL6 WT or iPLA2-KO mice were
used for in vivo studies. iPLA2-KO mice were generated in the laboratory
of Richard Gross and have been described previously (18). Mice were
infected with the Tulahuén strain blood form trypomastigotes (5,000
BFT; subcutaneous infection) and sacrificed 14 days postinfection. Hearts
were collected and frozen in liquid nitrogen before processing for bio-
chemical analysis.
Phospholipase A2 activity. HL-1 cells were grown to confluence and
exposed to the different experimental conditions. At the end of the exper-
imental intervention, the medium was rapidly removed; the cells were
washed with ice-cold PBS; 1 ml of ice-cold PLA2 activity buffer containing
(per liter) 250 mmol sucrose, 10 mmol KCl, 10 mmol imidazole, 5 mmol
EDTA, and 2 mmol dithiothreitol (DTT) with 10% glycerol, pH 7.8, was
added to each well; and the cells were removed from the plate using a cell
scraper. Similarly, mouse hearts were flash frozen and homogenized in
PLA2 buffer following collection at day 14 postinfection.
The suspension was sonicated on ice six times for 10 s each time (using
a microtip probe at 20% power output; 500 Sonic Dismembrator; Fisher
Scientific), and the sonicate was centrifuged at 20,000  g for 20 min to
remove cellular debris and nuclei. The pellet was resuspended in PLA2
activity buffer, and activity was determined by incubating the enzyme (50
g protein) with 100 M (16:0, [3H]18:1) plasmenylcholine substrate in
assay buffer containing (per liter) 10 mmol Tris, 4 mmol EGTA, 10%
glycerol, pH 7.0, at 37°C for 5 min in a total volume of 200 l. The
radiolabeled phospholipid substrate was introduced into the incubation
mixture by injection in 5 l ethanol to initiate the assay. Reactions were
terminated by the addition of 100 l butanol, and the released radiola-
beled fatty acid was isolated by the application of 25 l of the butanol
phase to channeled Silica Gel G plates, development in petroleum ether-
diethyl ether-acetic acid (70/30/1 [vol/vol/vol]), and subsequent quanti-
fication by liquid scintillation spectrometry. The protein content of each
sample was determined by the Lowry method utilizing freeze-dried bo-
vine serum albumin as the protein standard.
Measurement of total arachidonic acid release. HL-1 cells grown in
35-mm culture dishes were incubated at 37°C with 3Ci [3H]arachidonic
acid for 18 h. This incubation resulted in70% incorporation of radio-
activity into the myocytes. After incubation, the myocytes were washed
three times with Tyrode solution containing 0.36% bovine serum albu-
min to remove unincorporated [3H]arachidonic acid. The cells were in-
cubated at 37°C for 15 min before being subjected to the experimental
conditions. At the end of the stimulation period, the supernatant was
removed and centrifuged at 2,000 g to remove any detached myocytes.
Myocytes attached to the tissue culture well were solubilized in 10% so-
dium dodecyl sulfate, and radioactivity in both supernatant and cells was
quantified by liquid scintillation spectrometry.
Measurement of PGE2 release from HL-1 cells. Myocytes were grown
to confluence in 16-mm tissue culture dishes. The cells were washed twice
with Hanks balanced salt solution (HBSS) containing (per liter) 135
mmol NaCl, 0.8 mmol MgSO4, 10 mmol HEPES (pH 7.6), 1.2 mmol
iPLA2 and Chagas’ Disease
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CaCl2, 5.4 mmol KCl, 0.4 mmol KH2PO4, and 6.6 mmol glucose. After
washing, 0.5 ml of HBSS with 0.36% bovine serum albumin (BSA) was
added to each culture well. The myocytes were then subjected to the ex-
perimental conditions, and the surrounding buffer was removed from the
cells after selected time intervals. Detached myocytes were removed by
centrifugation at 2,000 g, and PGE2 release was measured immediately
using an immunoassay kit (R&D Systems, Minneapolis, MN).
Measurement of PGE2 content by MS. PGE2 was quantified by liquid
chromatography-tandem mass spectrometry (LC–MS-MS) using a
method adapted from Degousee and coworkers (19). In brief, 25 mg of
freeze-clamped and pulverized ventricular tissue was homogenized on ice
in 125l of phosphate-buffered saline and 40l of methanol (containing
deuterated PGE2 internal standard). Eicosanoids were then extracted
twice into a volume of 600l, and ethyl acetate was subsequently added to
the tissue homogenate and thoroughly mixed for 30 s. The pooled ethyl
acetate extracts were then dried under nitrogen and resuspended in 50 l
acetonitrile-water-formic acid (20:80:0.0025 [vol/vol/vol]) prior to LC–
MS-MS. Thirty microliters was injected onto a Supelco Discovery HS C18
column (150 mm by 2.1-mm inside diameter [i.d.]; 5-m particle size) as
the stationary phase, with binary discontinuous linear gradient elution
using mobile phases A (0.1% formic acid in water) and B (0.1% formic
acid in methanol) at a flow rate of 0.4 ml/min. The initial mobile phase
was comprised of 80% A with sequential linear gradients to 62% A (over 5
min), 50% A (over 10 min), 40% A (over 13 min), and 10% A (over 2
min). Following the linear gradients, the mobile phase was maintained for
3 min at 10% A, followed by a return to the initial conditions. A Thermo
Fisher Quantum Ultra triple-quadrupole tandem mass spectrometer was
operated in negative ion mode. Argon was used as the collision gas at 1
atm with collision energy at 17 eV. Electrospray ionization conditions
included voltage set at 4,000 eV, sheath pressure at 40 arbitrary units,
auxiliary pressure at 10 arbitrary units, and temperature at 310°C. Selected
reaction monitoring of m/z 351.23 to m/z 270.95 for [3,3,4,4-d4]-PGE2
and m/z 355.25 to m/z 275.03 for PGE2 was used to detect PGE2 (Rt 17
min). Authentic PGE2 (14010) and the internal standard, [3,3,4,4-d4]-
PGE2 (10007273), were purchased from Cayman Chemicals and were
used to confirm calibration factors for quantification of PGE2 from peak
areas.
PAF assay. Cardiac myocytes were grown in 16-mm tissue culture
dishes and washed twice with Hanks balanced salt solution containing 135
mM NaCl, 0.8 mM MgSO4, 10 mM HEPES (pH 7.4), 1.2 mM CaCl2, 5.4
mM KCl, 0.4 mM KH2PO4, 0.3 mM Na2HPO4, and 6.6 mM glucose and
incubated with 50 Ci [3H]acetic acid for 20 min. After the selected time
interval for incubation with the appropriate agents, lipids were extracted
from the cells by the method of Bligh and Dyer (20). The chloroform layer
was concentrated by evaporation under N2, applied to a silica gel 60
(Merck) thin-layer chromatography (TLC) plate, and developed in chlo-
roform-methanol-acetic acid-water (50/25/8/4 [vol/vol/vol/vol]). The re-
gion corresponding to PAF was scraped, and radioactivity was quantified
using liquid scintillation spectrometry. Loss of PAF during extraction and
chromatography was corrected for by adding a known amount of
[14C]PAF as an internal standard. [14C]PAF was synthesized by acetylat-
ing the sn-2 position of lyso-PAF with [14C]acetic anhydride using 0.33 M
dimethylaminopyridine as a catalyst. The synthesized [14C]PAF was pu-
rified by high-performance liquid chromatography (HPLC).
RAW cell adherence. RAW 264.7 cells were grown to confluence in
Dulbecco’s modified Eagle’s medium with 10% fetal bovine serum. Cell
suspensions (10 106/ml) were labeled with 4 g/ml calcein-AM for 45
min at 37°C. The cells were washed three times with HEPES buffer and
resuspended at a concentration of 4 106/ml, and 0.5 ml was added to the
confluent mouse cardiac myocyte cell layer. At the end of the incubation
time, nonadherent cells were removed and adherent cells and cardiac
myocytes were lysed in 1 ml of 0.2% Triton X-100. Calcein fluorescence in
each sample was measured at an excitation wavelength of 485 nm and an
emission wavelength of 530 nm. The percent cell adherence in each sam-
ple was calculated based upon the fluorescence measured in 0.5 ml of
RAW 264.7 cell suspension.
Measurement of parasitemia. Circulating parasites from samples of
fresh blood collected from each mouse at day 14 postinfection were
counted. Blood was obtained by cardiac puncture, 1.5l was placed under
a 12-mm round coverslip, and 25 high-power (40) fields were counted.
This method of parasitemia estimation has a lower-sensitivity detection
limit of 16,740 BFT/ml.
Real-time PCR detection of T. cruzi in mouse tissue. The hearts of
WT and iPLA2-KO mice were harvested 14 days postinfection with T.
cruzi. DNA samples were purified using a DNeasy kit (Qiagen, Valencia,
CA), and the total DNA concentration was adjusted to 40 ng/l. Primers
(5=-AACCACCACGACAACCACAA-3= and 5=-TGCAGGACATCTGCA
CAAAGTA-3=) were used to specifically amplify a 65-bp fragment of cru-
zipain, as described previously (21). However, instead of SYBR green de-
tection, as described in the previous method, the amplicon generation was
detected using a 6-carboxyfluorescein– 6-carboxytetramethylrhodamine
(FAM-TAMRA) probe (5=-TGCCCCAGGACCGTCCCCA-3=; Synthe-
gen, Houston, TX) and TaqMan PCR master mix (Applied Biosystems,
Carlsbad, CA) (a 900-nm concentration of each primer and 200 ng of
sample DNA). A standard curve was generated using positive-control
DNA harvested from a known concentration of T. cruzi epimastigotes
grown in pure culture. These reactions were run in an Applied Biosystems
7500 Fast Instrument under the following conditions: 95°C for 10 min,
followed by 40 cycles of 95°C for 15 s and 60°C for 1 min. Analysis of T.
cruzi molecular equivalents (mEq) was performed by using Applied Bio-
systems 7500 software v2.0.1.
Statistical analysis. Statistical comparison of values was performed by
Student’s t test or one-way analysis of variance, with post hoc analysis
performed using Dunnet’s test. All results are expressed as mean stan-
dard error of the mean (SEM). Statistical significance was considered to be
a P value of0.05.
RESULTS
Measurement of PLA2 activity in cardiac myocytes. HL-1 cells
were incubated with increasing concentrations of either (R)- or
(S)-BEL for 10 min, and iPLA2 activity was measured. TheR and S
enantiomers of BEL are 10-fold more selective for iPLA2 and
iPLA2, respectively (22). PLA2 activity was measured in the ab-
sence of Ca2	 (4 mM EGTA) and using (16:0, [3H] 18:1) plasme-
nylcholine as the substrate. As shown in Fig. 1, pretreatment with
(R)-BEL to inhibit iPLA2 resulted in significantly greater inhibi-
tion of iPLA2 activity than when cells were pretreated with (S)-
BEL at the corresponding concentration. Thus, we conclude that
the majority of iPLA2 activity in HL-1 cells is iPLA2.
Arachidonic acid release. HL-1 cells were pretreated with ei-
ther (R)- or (S)-BEL (2 M; 10 min) prior to the addition of T.
cruzi (MOI, 0.2), after which arachidonic acid release was mea-
sured for up to 24 h. T. cruzi infection resulted in a significant
increase in arachidonic acid release that was evident after 12 h
(Fig. 2A). Increased arachidonic acid release in response toT. cruzi
infection was not affected by (S)-BEL pretreatment, but a signifi-
cant inhibition of T. cruzi-induced arachidonic acid release was
observed with (R)-BEL pretreatment. In similar experiments,
thrombin (0.1 IU/ml) was added to HL-1 cells and arachidonic
acid release was measured for up to 30 min, with or without pre-
treatment with either (R)- or (S)-BEL. Arachidonic acid release
from cardiac myocytes was increased in response to thrombin
(Fig. 2B). Pretreatment with (R)-BEL inhibited thrombin-in-
duced arachidonic acid release, whereas pretreatment with (S)-
BEL did not affect arachidonic acid release significantly. Thus,
iPLA2 is predominantly responsible for arachidonic acid release
Sharma et al.
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from mouse atrial myocytes following either T. cruzi infection or
thrombin stimulation.
PGE2 release. Cardiac myocytes infected with T. cruzi show a
significant increase in PGE2 release 24 to 48 h postinfection
(Fig. 3A). Similar to what was seen for arachidonic acid release,
(S)-BEL pretreatment did not affect PGE2 release; however, pre-
treatment with (R)-BEL resulted in significantly reduced PGE2
release. Likewise, thrombin (0.1 IU/ml)-treated cells had a signif-
icant increase in PGE2 release, observed over time (Fig. 3B). As
with T. cruzi infection, (S)-BEL pretreatment did not affect
thrombin-stimulated PGE2 release; however, (R)-BEL inhibits
thrombin-stimulated PGE2 release (Fig. 3B). These data suggest
that iPLA2 is critical in regulating release of PGE2 from cardiac
myocytes following T. cruzi infection.
Arachidonic acid and PGE2 release were measured under sim-
ilar experimental conditions using H9C2 cells, a rat cardiomyo-
blast cell line. H9C2 cells infected with T. cruzi also showed a
significant increase in arachidonic acid and PGE2 release that was
inhibited by pretreatment with (R)-BEL, but not by pretreatment
with (S)-BEL (data not shown).
PAF production. In response to T. cruzi infection, there was a
slight increase in PAF production that did not reach significance
and was unaffected by pretreatment with either (R)- or (S)-BEL
(Fig. 4A). However, incubating myocytes with thrombin (1 IU/
ml) resulted in a significant increase in PAF production over time
(Fig. 4B). In contrast to arachidonic acid and PGE2 release, (R)-
BEL does not affect thrombin-mediated PAF production, whereas
(S)-BEL significantly inhibits it. Thus, iPLA2 does not contribute
significantly to PAF production in cardiac myocytes, and the me-
diator is produced by iPLA2 activation in response to thrombin
stimulation (Fig. 4B). Hence, in response to thrombin stimula-
tion, PAF production is regulated by iPLA2 and not by iPLA2.
RAW cell adherence. To evaluate the functional impact of PAF
production on recruitment of inflammatory cells, we measured
the adherence of calcein-labeled mouse monocytes/macrophages,
RAW 264.7 cells, to cardiac myocytes following T. cruzi infection
or thrombin stimulation. Infection of cardiac myocytes with T.
cruzi caused no significant changes in RAW 264.7 cell adherence
(Fig. 5A). This is in agreement with the absence of PAF production
FIG 1 Inhibition of iPLA2 activity in mouse cardiac myocytes treated with
either (R)- or (S)-BEL (10-min pretreatment). Cardiac myocytes were incu-
bated with BEL (10 min). PLA2 activity was measured using 100 M (16:0,
[3H]18:1) plasmenylcholine in the presence of 4 mM EGTA. *, P 0.05, and
**, P 0.01, compared to activity measured in the absence of BEL. The values
shown are means SEM for 4 separate cell cultures.
FIG 2 (A) Increase in arachidonic acid release from T. cruzi (MOI, 0.2)-
infected cardiac myocytes in the presence or absence of pretreatment with (R)-
or (S)-BEL (2 M; 10 min). **, P  0.01 compared to unstimulated release,
and 		, P  0.01 when comparing results for T. cruzi-infected myocytes in
the presence or absence of BEL. The values shown are means  SEM for 4
separate cell cultures. (B) Increase in arachidonic acid release from thrombin-
stimulated (0.1 IU/ml) mouse cardiac myocytes with or without pretreatment
(10 min) with (R)- or (S)-BEL (2M). **, P 0.01 compared to unstimulated
release, and 		, P  0.01 when comparing results for thrombin-stimulated
myocytes in the presence or absence of (R)-BEL. The values shown are
means SEM for 4 separate cell cultures.
iPLA2 and Chagas’ Disease
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in T. cruzi-infected myocytes (Fig. 4A). Pretreating RAW 264.7
cells with CV3988, a PAF receptor antagonist, completely inhibits
macrophage/monocte adherence to T. cruzi-infected HL-1 cells.
Following thrombin stimulation, a significant increase in RAW
264.7 cell adherence was observed (Fig. 5B) with a time course
similar to that observed for increased PAF production (Fig. 4B).
RAW 264.7 cell adherence to thrombin-stimulated HL-1 cells was
inhibited by (S)-BEL pretreatment, but not by pretreatment with
(R)-BEL (Fig. 5B).
Studies in iPLA2-KO mice. In vitro studies indicate that
iPLA2 is crucial for the production of arachidonic acid and PGE2.
To understand its physiological relevance in Chagas’ disease, WT
and iPLA2-KO mice were infected with T. cruzi and observed
over a period of 42 days (6 weeks). By day 21, all the iPLA2-KO
mice died, but over 50% of the WT mice were still alive (Fig. 6).
Thus, iPLA2-KO mice are more susceptible to infection than WT
mice. Given this time course, differences in pathology and bio-
chemical changes may be pronounced just prior to the onset of
mortality, i.e., day 14. Hence, in the subsequent experiments, mice
FIG 3 (A) Increase in PGE2 release from T. cruzi-infected (MOI, 0.2) mouse
cardiac myocytes with or without pretreatment with (R)- or (S)-BEL (2M; 10
min). **, P 0.01 compared to unstimulated release. and		, P 0.01 when
comparing results for T. cruzi-infected myocytes in the presence or absence of
(R)-BEL. The values shown are means SEM for 6 separate cell cultures. (B)
Increase in PGE2 release from thrombin-stimulated (0.1 IU/ml) mouse cardiac
myocytes with or without pretreatment with (R)- or (S)-BEL (2 M; 10 min).
**, P  0.01 compared to unstimulated release, and 		, P  0.01 when
comparing results for thrombin-stimulated myocytes in the presence or ab-
sence of (R)-BEL. The values shown are means  SEM for 6 separate cell
cultures.
FIG 4 (A) PAF production in mouse cardiac myocytes infected with T. cruzi
(MOI, 0.2) with or without (R)- or (S)-BEL pretreatment (2M; 10 min). The
values shown are means SEM for 6 separate cell cultures. (B) PAF produc-
tion in mouse cardiac myocytes stimulated with thrombin (1 IU/ml) with or
without pretreatment with (R)- or (S)-BEL (2 M; 10 min). *, P 0.05, and
**, P 0.01 compared with values for unstimulated myocytes, and		, P
0.01 when comparing values in the presence or absence of BEL. The values
shown are means SEM for 8 separate cell cultures.
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were sacrificed 14 days postinfection; fresh blood samples were
collected to measure parasitemia; and hearts were isolated to mea-
sure tissue parasitism, enzyme activity, and eicosanoid produc-
tion.
Parasitemia and tissue parasitism. The number of circulating
parasites was significantly higher in iPLA2-KO mice than in WT
mice after 14 days of infection (Fig. 7A). Since microscopic exam-
ination of tissues has limited sensitivity, a PCR-based amplifica-
tion technique was used to accurately identify the presence of
parasites in tissues. Corresponding to the higher levels of circulat-
ing parasites, an increase in the number of parasites in the hearts of
iPLA2-KO mice compared to WT mice was also observed
(Fig. 7B).
Biochemical changes in the heart. A significant increase was
observed in cardiac iPLA2 activity in infected WT mice compared
to uninfected mice. Further, the iPLA2-KO mice showed no
change in cardiac iPLA2 activity following infection (Fig. 8). Thus,
T. cruzi infection leads to activation of iPLA2 in the heart, the
absence of which is detrimental to survival. Reduced iPLA2 activ-
ity in the KO hearts suggests that these mice could also have im-
paired eicosanoid production. On measuring the PGE2 content in
the heart, the iPLA2-KO mice were found to have significantly
less of the eicosanoid than WT mice (Fig. 9). These data are in
agreement with our in vitro observations and demonstrate the
importance of myocardial iPLA2 and eicosanoid production fol-
lowing T. cruzi infection.
DISCUSSION
Despite knowing the etiology of Chagas’ disease for over a century,
successful treatment strategies are still elusive. So far, only two
drugs, benznidazole and nifurtimox, are widely used for the treat-
ment of the disease, and both are known to cause severe side ef-
fects. Adverse effects include digestive problems, hematological
changes, dermatological alterations and neurological alterations
(23, 24). Though both drugs are recommended, their efficacies are
variable, and more information is needed to verify their ability to
clear the parasites. The fact that only two drugs exist to treat a
disease that has been prevalent for so long highlights the “ne-
glected” status of Chagas’ disease. Several challenges have im-
paired the development of therapeutic strategies, and much re-
mains unknown about vector-host interactions and the
mechanisms behind the various pathological symptoms associ-
ated with the disease. Only recently has it been determined that the
FIG 5 (A) RAW 264.7 cell adherence to mouse cardiac myocytes infected with
T. cruzi (MOI, 0.2) with or without pretreatment with (R)- or (S)-BEL (2M;
10 min). Where indicated, RAW 264.7 cells were incubated with the PAF
receptor antagonist CV3988 (10 M; 10 min). (B) RAW 264.7 cell adherence
to mouse cardiac myocytes stimulated with thrombin (1 IU/ml) with or with-
out pretreatment with (R)- or (S)-BEL (2 M; 10 min). Where indicated,
RAW 264.7 cells were incubated with the PAF receptor antagonist CV3988 (10
M; 10 min). *, P  0.05 compared to unstimulated control; *, P  0.05
compared to unstimulated RAW 264.7 cell adherence. The values shown are
means SEM for 4 separate cell cultures.
FIG 6 Survival curve (%) for WT (n  13) and iPLA2-KO (n  19) mice
following infection with the Tulahuén strain of T. cruzi (5,000 BFT; subcuta-
neous injection).
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chronic stages of the disease are associated with parasite persis-
tence and that autoimmune mechanisms may not be responsible
for organ damage, as hypothesized for several decades previously
(25). Since the presence of parasites is critical for the disease, it is
necessary to decipher the cascade of events that occur following
infection, increasing our understanding and the potential to cre-
ate drugs that can effectively treat the disease.
Several downstream metabolites of PLA2 have been implicated
in Chagas’ disease, but little is known about the direct contribu-
tion of the enzyme to the pathogenesis of the disease. Bioactive
lipids, such as eicosanoids and PAF, are potent inflammatory mol-
ecules produced by the action of PLA2 on membrane phospholip-
ids. Previous studies have outlined the varying roles of eicosanoids
in Chagas’ disease. Michelin et al. have suggested an immunosup-
pressive role for PGE2, upregulated via concanavalin A stimula-
tion of COX-2 in T. cruzi-infected spleen cells (26). Abdalla et al.
demonstrated that inhibition of COX-2-mediated PGE2 produc-
tion resulted in reduced inflammation, parasite pseudocysts, and
fibrosis in the hearts of infected mice, suggesting that PGE2 con-
tributes to cardiac damage in the acute phase of infection (27).
Cardoni et al. concluded from their studies that COX-2-derived
mediators are protective during the acute stages of T. cruzi infec-
tion but could be responsible for tissue damage in the chronic
stages. More recent studies by Ashton et al. have suggested that
TXA2 is an important parasite-derived eicosanoid that contrib-
utes to parasite proliferation and hence the inflammatory re-
sponse (28). Several studies also suggest that eicosanoids, in con-
junction with cytokines, chemokines, and other inflammatory
mediators, are essential for the progression and perpetuation of
the chronic phase of the disease (9, 29). Since PLA2 is critical for
arachidonic acid release and eicosanoid production, it could con-
FIG 7 (A) Parasitemia at day 14 in WT and iPLA2-KO mice following infec-
tion with the Tulahuén strain of T. cruzi (5,000 BFT; subcutaneous injection).
*, P 0.05 compared to the WT. The values shown are means and SEM; n
6. (B)T. cruzimolecular equivalents (TcME), quantified usingT. cruzi-specific
quantitative PCR (qPCR), from DNA isolated from the hearts of WT and
iPLA2-KO mice 14 days postinfection. *, P 0.05 compared to the WT. The
values shown are means and SEM; n 6.
FIG 8 iPLA2 activity in the hearts of WT and iPLA2-KO mice 14 days postin-
fection with T. cruzi. Shown is PLA2 activity, measured using 100 M (16:0,
[3H]18:1) plasmenylcholine in the presence of 4 mM EGTA. **, P  0.01
compared to activity measured in the uninfected heart. The values shown are
means and SEM; n 6.
FIG 9 PGE2 content in the hearts of WT and iPLA2-KO mice 14 days postin-
fection with T. cruzi. 	, P  0.05, and 		, P  0.01, compared to activity
measured in the WT heart. The values shown are means and SEM; n 6.
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tribute to the pathogenesis of Chagas’ disease via the formation of
these mediators.
The predominant phospholipase A2 in the heart, iPLA2, is
known to have two major isoforms in mammalian cells, iPLA2
and iPLA2. While both isoforms are present in cardiac tissue, it
has been determined in these studies and in previous work from
our laboratory that most of the cardiac iPLA2 activity is attribut-
able to the  isoform of the enzyme (15). In order to differentiate
between the functions of the two isoforms, pharmacological in-
hibitors, (R)- and (S)-BEL, are commonly used (22). BEL has been
demonstrated to have 100-fold selectivity for iPLA2 versus cyto-
solic PLA2 (cPLA2) and secretory PLA2 (sPLA2) isoforms, and its
enantiomers, (R)- and (S)-BEL, are 10-fold more selective for
iPLA2 and iPLA2, respectively (30). Previously, we determined
that iPLA2 has a preference for the arachidonylated plasmalogen
phospholipid species, which are abundant in the sarcolemma of
cardiac myocytes (14). Serine proteases, such as thrombin, were
shown to activate iPLA2 via the protease-activated receptors
(PARs) present on the myocyte surface, and based on pharmaco-
logical inhibition, iPLA2was established as the predominant iso-
form in cardiac myocytes (13, 16). Since arachidonic acid release,
the rate-limiting step in eicosanoid production, is generated
by the action of phospholipases, it is likely that iPLA2 contributes
to the production of this critical mediator. However, until the
present study, the effect of T. cruzi on cardiac iPLA2 has not been
investigated.
Other members of the PLA2 family also exist in the myocar-
dium and are grouped based on their structures, substrate prefer-
ences, and requirements for calcium. cPLA2 enzymes are selective
for arachydonylated choline phospholipids but do not demon-
strate any preference for sn-1 vinyl ether linkages (plasmalogens)
and contribute to the formation of eicosanoids in response to
extracellular signals (31). In the heart, cPLA2 is known to regulate
cardiac hypertrophy and plays a protective role in ischemia reper-
fusion injury (32, 33). sPLA2s do not exhibit any preference for the
sn-2 fatty acid but are proposed to play a role in eicosanoid for-
mation in the heart (31). It has also been suggested that sPLA2 may
be involved in regulating cardiac hypertrophy (34). iPLA2 en-
zymes are selective for plasmalogen phospholipids, which are se-
lectively enriched in the sarcolemma of myocardial cells. Also, the
majority of the myocardial arachidonic acid is esterified to plas-
malogen species, making plasmalogens a rich source of the arachi-
donic acid required for eicosanoid production following hydroly-
sis by iPLA2. The contribution of any of the PLA2 isoforms to T.
cruzi infection remains largely unknown. It is possible that both
cPLA2 and sPLA2 contribute to the progression of Chagas’ heart
disease; however, since the majority of the myocardial PLA2 activ-
ity is attributable to iPLA2, we have explored the role of this iso-
form in acute Chagas’ disease.
We used the mouse atrial cardiac myocyte cell line (HL-1 cells),
as well as a knockout mouse model, to demonstrate the role of
iPLA2 in acute T. cruzi infection. In mouse cardiac myocytes, the
inhibition of iPLA2 activity is much more sensitive to (R)-BEL
than to (S)-BEL, suggesting that iPLA2 is the predominant iso-
form in these cells. An iPLA2-mediated increase in arachidonic
acid and PGE2 release was also observed following treatment with
thrombin or T. cruzi infection of cardiac myocytes. Hence, this
isoform may be critical for controlling the rate-limiting step in
eicosanoid production. The mouse model of infection revealed
that iPLA2 is important in acute infection, since the iPLA2-KO
mice exhibited early mortality compared to WT mice. Prior to the
onset of mortality in either group (day 14 postinfection), WT mice
showed increased cardiac iPLA2 activity and less parasitemia and
tissue parasitism, unlike that observed in the iPLA2-KO mice.
Hence, the absence of iPLA2 results in a higher parasite load and
mortality, suggesting a protective role for the isoform in acute T.
cruzi infection.
Previous studies by Mukherjee et al. suggest that COX-1 inhi-
bition by aspirin leads to increased parasitemia and mortality inT.
cruzi-infected mice. These findings were not mimicked entirely in
COX-1 knockout mice, which show increased parasitemia, but
not enhanced mortality. Based on these findings, it was hypothe-
sized that COX-1-mediated inhibition of eicosanoids contributed
to increased parasitemia but did not affect mortality and that as-
pirin-mediated increase in mortality is likely due to “off-target”
effects of the drug. Our findings, in the absence of any pharmaco-
logical inhibitors, show that the reduced eicosanoids and in-
creased parasite load associated with mortality are due to the ab-
sence of iPLA2.
Another important PLA2-derived mediator, PAF, is responsi-
ble for the activation and transmigration of inflammatory cells to
relevant sites (35). The role of PAF in cardiac inflammation fol-
lowingT. cruzi infection is largely unknown. It has been suggested
that PAF induces the production of nitric oxide in T. cruzi-in-
fected macrophages and hence is protective (36). PAFR
/
 mice
infected with T. cruzi were shown to have an increased number of
parasite pseudocysts and inflammation in the heart and hence are
more susceptible to infection than WT mice (37). In this study,
cardiac myocytes infected with T. cruzi did not show a significant
increase in PAF production. Thrombin treatment however, did
result in a considerable increase in PAF production, which is me-
diated by iPLA2 and not iPLA2.
The presence of microthrombi and platelet aggregation have
been observed in Chagasic hearts, suggesting an increase in
thrombin in the myocardium (12, 38). Pinazo et al. have also
demonstrated that a prothrombotic state exists in chronic Chagas’
disease patients, as they have significantly increased endogenous
thrombin potential and prothrombin fragment 1 	 2, which
serves as a marker for thrombin generation (39). Thus, while the
parasite itself may not directly affect PAF production in cardiac
myocytes, other associated factors present in the vicinity of infec-
tion could enhance the process. These findings suggest a protec-
tive role for iPLA2 in acute infection via the production of PAF
and its effects on macrophages, but this needs further investiga-
tion. The disparity in PAF production with T. cruzi infection ver-
sus thrombin pretreatment is not known but may be related to
differences in intracellular events initiated by activation of the
thrombin receptor and those initiated by infection with T. cruzi.
In previous studies, we have demonstrated that there is an imme-
diate increase in PAF production in response to thrombin stimu-
lation of endothelial cells (35). Our data here show a similar in-
crease in PAF production in cardiac myocytes stimulated with
thrombin. We propose that this is due to tight coupling between
the thrombin receptor and iPLA2 activation. Our data here sug-
gest that thrombin activates HL-1 cell iPLA2 and iPLA2,
whereas T. cruzi infection results in iPLA2 activation only and
may be related to more delayed intracellular processes. Regardless
of changes in PAF production, RAW cell adherence remained un-
changed, suggesting that increased PAF production does not play
a direct role in inflammatory-cell adherence to cardiac myocytes.
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In conclusion, these studies suggest that, following T. cruzi infec-
tion, the subsequent increase in arachidonic acid and eicosanoid
levels is mediated by iPLA2, the predominant PLA2 isoform in
these cells. Thrombin stimulation has a similar effect on iPLA2
but, additionally, causes increased PAF production, mediated by
iPLA2.
Several studies have suggested that eicosanoids produced dur-
ing the acute stage of the disease are important immunomodula-
tors, enabling the disease to progress into its chronic stages. Thus,
iPLA2 contributes to this process via eicosanoid production,
which in turn affects parasite persistence and disease progression,
forming a critical link between the parasite and the host. Our
studies indicate that iPLA2 activation is beneficial during acute
infection, elucidated by the early mortality observed in
iPLA2-KO mice following infection. While many questions re-
main, clearly, iPLA2 is critical in the setting of T. cruzi infection.
Understanding its role during the acute stages of the disease may
thus help us recognize important events during infection that may
impact the chronic stages and present us with more points of
intervention and treatment of Chagas’ disease.
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